Crossmark

Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study

Crossref DOI link: https://doi.org/10.1016/j.arteri.2023.04.004

Published Print: 2023-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Blanco Echevarría, Agustín

García Díaz, Juan De Dios

Caixas, Assumpta

Plana Gil, Núria

Rico Corral, Miguel Ángel

Bridges, Ian

Dhalwani, Nafeesa

Gatell Menchen, Sònia

Ray, Kausik K.
Funding

Funding for this research was provided by:

Amgen
License Information

Text and Data Mining valid from 2023-11-01

Version of Record valid from 2023-05-08
More Information

This article is maintained by: Elsevier

Article Title: Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study

Journal Title: Clínica e Investigación en Arteriosclerosis

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.arteri.2023.04.004

Content Type: article

Copyright: © 2023 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Arteriosclerosis.

Document is current

Any future updates will be listed below